Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ups J Med Sci ; 1292024.
Artigo em Inglês | MEDLINE | ID: mdl-38863729

RESUMO

Background: Standard dosages of analgesic and sedative drugs are given to intensive care patients. The resulting range of blood concentrations and corresponding clinical responses need to be better examined. The purpose of this study was to describe daily dosages, measured blood concentrations, and clinical responses in critically ill patients. The purpose was also to contribute to establishing whole blood concentration reference values of the drugs investigated. Methods: A descriptive study of prospectively collected data from 302 admissions to a general intensive care unit (ICU) at a university hospital. Ten drugs (clonidine, fentanyl, morphine, dexmedetomidine, ketamine, ketobemidone, midazolam, paracetamol, propofol, and thiopental) were investigated, and daily dosages recorded. Blood samples were collected twice daily, and drug concentrations were measured. Clinical responses were registered using Richmond agitation-sedation scale (RASS) and Numeric rating scale (NRS). Results: Drug dosages were within recommended dose ranges. Blood concentrations for all 10 drugs showed a wide variation within the cohort, but only 3% were above therapeutic interval where clonidine (57 of 122) and midazolam (38 of 122) dominated. RASS and NRS were not correlated to drug concentrations. Conclusion: Using recommended dose intervals for analgesic and sedative drugs in the ICU setting combined with regular monitoring of clinical responses such as RASS and NRS leads to 97% of concentrations being below the upper limit in the therapeutic interval. This study contributes to whole blood drug concentration reference values regarding these 10 drugs.


Assuntos
Analgésicos , Hipnóticos e Sedativos , Unidades de Terapia Intensiva , Midazolam , Humanos , Hipnóticos e Sedativos/administração & dosagem , Hipnóticos e Sedativos/farmacocinética , Hipnóticos e Sedativos/sangue , Analgésicos/administração & dosagem , Analgésicos/farmacocinética , Analgésicos/sangue , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Estudos Prospectivos , Adulto , Midazolam/administração & dosagem , Midazolam/farmacocinética , Midazolam/sangue , Cuidados Críticos/métodos , Dexmedetomidina/administração & dosagem , Dexmedetomidina/farmacocinética , Dexmedetomidina/sangue , Fentanila/administração & dosagem , Fentanila/sangue , Fentanila/farmacocinética , Estado Terminal , Propofol/administração & dosagem , Propofol/farmacocinética , Propofol/sangue , Clonidina/administração & dosagem , Clonidina/farmacocinética , Clonidina/sangue , Ketamina/administração & dosagem , Ketamina/sangue , Ketamina/farmacocinética , Morfina/administração & dosagem , Morfina/sangue , Morfina/farmacocinética , Idoso de 80 Anos ou mais , Relação Dose-Resposta a Droga , Tiopental/administração & dosagem , Tiopental/farmacocinética , Acetaminofen/administração & dosagem , Acetaminofen/sangue , Acetaminofen/farmacocinética
2.
Forensic Sci Int ; 275: 76-82, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28324770

RESUMO

INTRODUCTION: 3-methoxyphencyclidine (3-MeO-PCP) appeared on the illicit drug market in 2011 and is an analogue of phencyclidine, which exhibits anesthetic, analgesic and hallucinogenic properties. In this paper, we report data from a non-fatal intoxication and seven deaths involving 3-MeO-PCP in Sweden during the period March 2014 until June 2016. CASE DESCRIPTIONS: The non-fatal intoxication case, a 19-year-old male with drug problems and a medical history of depression, was found awake but tachycardic, hypertensive, tachypnoeic and catatonic at home. After being hospitalized, his condition worsened as he developed a fever and lactic acidosis concomitant with psychomotor agitation and hallucinations. After 22h of intensive care, the patient had made a complete recovery. During his hospitalization, a total of four blood samples were collected at different time points. The seven autopsy cases, six males and one female, were all in their twenties to thirties with psychiatric problems and/or an ongoing drug abuse. METHODS: 3-MeO-PCP was identified with liquid chromatography (LC)/time-of-flight technology and quantified using LC-tandem mass spectrometry. RESULTS: In the clinical case, the concentration of 3-MeO-PCP was 0.14µg/g at admission, 0.08µg/g 2.5h after admission, 0.06µg/g 5h after admission and 0.04µg/g 17h after admission. The half-life of 3-MeO-PCP was estimated to 11h. In the autopsy cases, femoral blood concentrations ranged from 0.05µg/g to 0.38µg/g. 3-MeO-PCP was the sole finding in the case with the highest concentration and the cause of death was established as intoxication with 3-MeO-PCP. In the remaining six autopsy cases, other medications and drugs of abuse were present as well. CONCLUSION: Despite being scheduled in January 2015, 3-MeO-PCP continues to be abused in Sweden. Exposure to 3-MeO-PCP may cause severe adverse events and even death, especially if the user does not receive life-supporting treatment.


Assuntos
Drogas Desenhadas/efeitos adversos , Drogas Desenhadas/intoxicação , Alucinógenos/efeitos adversos , Alucinógenos/intoxicação , Fenciclidina/análogos & derivados , Adulto , Acatisia Induzida por Medicamentos , Catatonia/induzido quimicamente , Cromatografia Líquida , Drogas Desenhadas/análise , Feminino , Meia-Vida , Alucinógenos/análise , Humanos , Hipertensão/induzido quimicamente , Masculino , Fenciclidina/efeitos adversos , Fenciclidina/análise , Fenciclidina/intoxicação , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Taquicardia/induzido quimicamente , Taquipneia/induzido quimicamente , Espectrometria de Massas em Tandem , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...